MCLEAN, Va. and BUDAPEST, Hungary, June 12 GeneticImmunity, a US/Hungarian clinical-stage Company focused on the development ofits patented nanomedicines for targeted immune amplification, announced todaythat the Company will be presenting at the 2008 Bio International Conventionto be held June 17-20, 2008 at the San Diego Convention Center in San Diego,CA. The Company's President and Chief Executive Officer, Dr. JuliannaLisziewicz, is scheduled to present at the following times:
For more information on this event please visit: http://www.bio2008.org.
While at the conference Genetic Immunity will discuss three partneringopportunities. The first is focused on DermaVir Patch, which is the Company'slead nanomedicine candidate for the treatment for HIV/AIDS. This topicallydelivered nanomedicine is designed to amplify HIV-specific memory T cellresponses in order to kill HIV-infected cells specifically while leaving thehealthy cells intact.
The second opportunity is DermaPrep, which is a novel and proprietarymedical device that supports the topical delivery of macromolecules to lymphnodes. DermaPrep is designed to mimic the body's response and has demonstratedproof of concept with through development of the DermaVir Patch.
The third partnering option is the Company's patented NanoCompnanoformulation technology that includes disease-specific, plasmid DNA-encodedantigens. It is designed to improve the immunigenicity of antigens and induceeffective immune responses. NanoComp has also demonstrated proof of conceptwith the DermaVir Patch, which includes HIV-specific plasmid DNA encodedantigens.
About Genetic Immunity(R)
Genetic Immunity is a US/Hungarian clinical stage biopharmaceuticalcompany establishing leadership in Nanomedicines for targeted immuneamplification. Nanomedicine, an offshoot of nanotechnology, refers to highlyspecific medical intervention at the molecular scale for curing diseases orrepairing damaged tissues. The Company aims to discover, develop andcommercialize topically administered nanomedicines that can create new marketsfor treating infectious diseases, cancer and allergies. These indicationsrepresent a significant unmet medical need and the potential for alternativetreatment approaches. The DermaVir Patch, Genetic Immunity's lead nanomedicinecandidate, is in Phase II clinical development and could be the firstnanomedicine immune therapy for HIV-infected individuals. The DermaVir Patchhas demonstrated excellent safety, immunogenicity and antiviral efficacy inpreclinical studies. Phase I/II trials to date have confirmed safety andtolerability and indicate the induction of long-lasting HIV-specific memory Tcells.
About the Nanomedicine Technology Platform
Genetic Immunity's nanomedicine immune amplification platform technologyis comprised of two principal components: NanoComp and DermaPrep. NanoComp isa patented nanoformulation technology that includes disease-specific plasmidDNA encoded antigens. DermaPrep is the topical administration device thatdelivers NanoComp into a patient's lymph node dendritic cells to induce T cellmediated immune responses that can treat a broad spectrum of diseases. Thesetwo components together make up the DermaVir Patch. The plasmid DNA withinDermaVir Patch's NanoComp nanoparticles is specific to HIV and topicallydelivered via DermaPrep to amplify the immune system to kill only HIV-infectedcells.-- Wednesday, May 18 at 2:00 p.m. (PT): Dr. Lisziewicz will present an overview of Genetic Immunity's nanomedicine technology platform and clinical programs on as part of the infectious disease tract in room 5B. -- Thursday, June 19th at 2:00 p.m. (PT): Dr. Lisziewicz will represent Genetic Immunity in an international case study, "Biotechnology in Hungary: Mission Possible," in room 26 AB.
SOURCE Genetic Immunity